Annexin Pharmaceuticals AB is a biotechnology company based in Stockholm that focuses on developing innovative pharmaceutical solutions aimed at empowering the body to combat various diseases. The company has a broad therapeutic coverage, with particular specialization in conditions such as retinal vein occlusion and cancer. Annexin is actively engaged in research and development to advance treatment options for patients, demonstrating a commitment to improving healthcare outcomes.
The company has received approval for a Phase 2a clinical study targeting diabetic retinopathy and retinal vein occlusion, highlighting its focus on addressing significant medical needs. Annexin also collaborates with a Medical Advisory Board composed of ophthalmology experts, which supports its efforts in enhancing therapeutic strategies. Additionally, the company participates in industry events like the Eyecelerator conference, furthering its engagement with the biotechnology community and investors to foster growth and innovation.